Profund Advisors LLC Purchases 13,334 Shares of GRAIL, Inc. $GRAL

Profund Advisors LLC grew its position in GRAIL, Inc. (NASDAQ:GRAL) by 141.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,776 shares of the company’s stock after buying an additional 13,334 shares during the quarter. Profund Advisors LLC’s holdings in GRAIL were worth $1,949,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GRAL. Royal Bank of Canada increased its stake in GRAIL by 17.7% in the first quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock valued at $2,250,000 after acquiring an additional 13,264 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in GRAIL by 28.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of GRAIL by 390.3% in the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after purchasing an additional 1,401 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of GRAIL by 37.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock valued at $2,362,000 after purchasing an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of GRAIL by 115.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock valued at $4,090,000 after purchasing an additional 42,675 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GRAL. Morgan Stanley lowered their price target on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Guggenheim reduced their price objective on GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Mizuho started coverage on shares of GRAIL in a report on Friday, April 10th. They issued a “neutral” rating and a $58.00 target price for the company. Finally, Piper Sandler raised their price target on shares of GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $67.88.

Insider Activity

In other news, CFO Aaron Freidin sold 45,806 shares of the business’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the sale, the chief financial officer directly owned 260,669 shares in the company, valued at approximately $13,012,596.48. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Joshua J. Ofman sold 61,665 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $3,078,316.80. Following the completion of the transaction, the president directly owned 371,216 shares of the company’s stock, valued at $18,531,102.72. This represents a 14.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 310,267 shares of company stock valued at $15,485,396. 1.83% of the stock is currently owned by corporate insiders.

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $66.03 on Thursday. GRAIL, Inc. has a 52-week low of $29.95 and a 52-week high of $118.84. The company has a market capitalization of $2.83 billion, a PE ratio of -6.37 and a beta of 3.03. The company has a fifty day moving average of $52.65 and a 200-day moving average of $76.88.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, beating the consensus estimate of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The company had revenue of $40.79 million for the quarter, compared to the consensus estimate of $39.16 million. On average, equities analysts forecast that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.